Food Allergy Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | DBV Technologies, Aravax, Xencor

Food Allergy Pipeline constitutes 25+ key companies continuously working towards developing 30+ Food Allergy treatment therapies, analyzes DelveInsight.

Food Allergy Overview:
Food allergies are harmful immune responses triggered by specific foods, which consistently occur upon exposure. These reactions can affect multiple body systems-such as the skin, digestive, respiratory, and cardiovascular systems-and can range from mild to life-threatening. Unlike food intolerances, food allergies involve the immune system and are typically more serious. They are increasingly common, especially in developed countries, affecting about 5-8% of children and 1-2% of adults globally.
Symptoms vary and may include hives, swelling, breathing difficulties, stomach issues, and, in severe cases, anaphylaxis-a potentially fatal reaction requiring immediate treatment. Food allergies are classified into three types based on immune mechanisms:
IgE-mediated (most common), involving immediate allergic reactions.

Non-IgE-mediated, typically causing delayed gastrointestinal symptoms.

Mixed-type, involving both mechanisms and presenting a combination of symptoms.

The development of food allergies is influenced by genetic and environmental factors, such as family history, early dietary exposure, the hygiene hypothesis, and possible vitamin D deficiency. Major allergens include milk, eggs, peanuts, tree nuts, soy, wheat, fish, and shellfish.
Diagnosis involves reviewing medical and dietary history, conducting skin and blood tests, and sometimes supervised food challenges. Management primarily consists of strict avoidance of trigger foods, education on food labeling, and emergency preparedness with epinephrine auto-injectors. Although new therapies like oral immunotherapy are being explored, they are not yet widely accessible. Overall, food allergies are a growing public health issue that require proper awareness, diagnosis, and management to prevent severe reactions.

Download our report @ https://www.delveinsight.com/report-store/food-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Food Allergy Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Food Allergy Therapeutics Market.

Key Takeaways from the Food Allergy Pipeline Report

DelveInsight's Food Allergy pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Food Allergy treatment.
In July 2024, the FDA expanded the approval of Palforzia, a peanut allergen powder, to include children aged one through three years. Previously approved for individuals aged four to seventeen, Palforzia helps mitigate allergic reactions, including anaphylaxis, that may occur with accidental peanut exposure. ​
In early 2024, the FDA approved Xolair (omalizumab) as the first medication to reduce allergic reactions to multiple food allergens after accidental exposure. Xolair is indicated for individuals aged one year and older with IgE-mediated food allergies. This approval offers a preventive treatment option beyond strict dietary avoidance.
Effective January 1, 2023, sesame was officially recognized as the ninth major food allergen in the U.S., following the enactment of the Food Allergy Safety, Treatment, Education, and Research (FASTER) Act. This designation requires sesame to be clearly labeled on packaged foods, enhancing safety for individuals with sesame allergies. ​
Key Food Allergy companies such as DBV Technologies, Aravax, Xencor, and others are evaluating new drugs for Food Allergy to improve the treatment landscape.
Promising Food Allergy pipeline therapies in various stages of development include Viaskin Peanut, PVX-108, AIMab7195, and others.

Food Allergy Pipeline Analysis
The Food Allergy pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Food Allergy Market.

Categorizes Food Allergy therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Food Allergy drugs under development based on:

Stage of development

Food Allergy Route of administration

Target receptor

Monotherapy vs. combination therapy

Food Allergy Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Food Allergy Licensing agreements

Funding and investment activities supporting future Food Allergy market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/food-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Food Allergy Emerging Drugs
Viaskin Peanut: DBV Technologies
PVX-108: Aravax
AIMab7195: Xencor

Food Allergy Companies

More than 25 leading companies are currently engaged in developing treatments for food allergies. Among them, DBV Technologies has a drug candidate that has reached the most advanced stage of development-preregistration.

DelveInsight's report covers around 30+ products under different phases of Food Allergy clinical trials like

Food Allergy Late stage Therapies (Phase III)
Food Allergy Mid-stage Therapies (Phase II)
Food Allergy Early-stage Therapies (Phase I)
Food Allergy Pre-clinical and Food Allergy Discovery stage Therapies
Food Allergy Discontinued & Inactive Therapies

Food Allergy pipeline report provides the Food Allergy therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Food Allergy Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Food Allergy Therapies and Key Food Allergy Companies: Food Allergy Clinical Trials and recent advancements https://www.delveinsight.com/report-store/food-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Food Allergy Pipeline Therapeutic Assessment
• Food Allergy Assessment by Product Type
• Food Allergy By Stage
• Food Allergy Assessment by Route of Administration
• Food Allergy Assessment by Molecule Type

Download Food Allergy Sample report to know in detail about the Food Allergy treatment market @ Food Allergy Therapeutic Assessment https://www.delveinsight.com/sample-request/food-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Food Allergy Current Treatment Patterns
4. Food Allergy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Food Allergy Late-Stage Products (Phase-III)
7. Food Allergy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Food Allergy Discontinued Products
13. Food Allergy Product Profiles
14. Food Allergy Key Companies
15. Food Allergy Key Products
16. Dormant and Discontinued Products
17. Food Allergy Unmet Needs
18. Food Allergy Future Perspectives
19. Food Allergy Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Food Allergy Pipeline Reports Offerings: https://www.delveinsight.com/report-store/food-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.